@article {1466913,
	title = {Management of Meibomian Gland Dysfunction: A Review},
	journal = {Surv Ophthalmol},
	year = {2019},
	month = {2019 Sep 05},
	abstract = {Meibomian gland dysfunction (MGD) is the leading cause of evaporative dry eye disease and is one of the most common conditions encountered by eye care providers. MGD is characterized by obstruction of the meibomian gland terminal ducts and/or changes in their glandular secretion, resulting in changes in tear film stability, inflammation, and symptoms of irritation. There is no gold standard treatment for MGD, but rather a diversity of options. Conservative measures include warm compresses and lid hygiene, but there is growing interest and need for medical treatments and procedures. Potential medical treatments include antibiotics, non-steroidal and steroidal anti-inflammatory agents, essential fatty acid supplementation, hormone therapy, and control of Demodex infestation. Procedures include intraductal meibomian gland probing, the use of electronic heating devices, intense pulsed light therapy, and intranasal neurostimulation. We provide an update on MGD treatments based on recent studies.},
	issn = {1879-3304},
	doi = {10.1016/j.survophthal.2019.08.007},
	author = {Sabeti, Saama and Kheirkhah, Ahmad and Yin, Jia and Dana, Reza}
}
